

INDICATION AND USAGE FOR SANDOSTATIN LAR DEPOT

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for

- Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
- Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors

In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

Please see additional Important Safety Information for Sandostatin LAR Depot on page 12 and for Sandostatin Immediate-Release Injection on page 13.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot.



What's Inside

The information in this brochure is organized by topic, so you can take it step by step—or jump ahead if you need to know something right away. Here is how this content is organized:

What Is Carcinoid Syndrome? 3 Getting to Know Sandostatin LAR Depot 4 5 Treatment With Sandostatin LAR Depot This Is RealSupport™ 6 Living With Carcinoid Syndrome 7 Food and Diet Changes 8 Carcinoid Syndrome Support Groups 9 Resources and Support 10 FAQs to Get You Started 11 Important Safety Information 12-13 **Notes** 14

IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN LAR DEPOT (CONTINUED)

Common Side Effects: Most patients experience side effects at some time. Some common side effects you may experience include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

Other Information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information for Sandostatin® LAR Depot (octreotide acetate) for injectable suspension on page 12 and for Sandostatin® (octreotide acetate) Immediate-Release Injection on page 13.


Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot.





What Is Carcinoid Syndrome?

- Carcinoid syndrome refers to the group of symptoms that result from active carcinoid tumors
- When carcinoid tumors start to spread, or metastasize, they can cause sudden and severe symptoms
- These symptoms, which can include severe diarrhea and flushing, are the result of an increased release of hormones by the carcinoid tumors



*Liver is a common site of metastases.

What causes the symptoms of carcinoid syndrome?

Neuroendocrine tumors (NET) form in the cells of the neuroendocrine system. NET can form in the digestive system or lung and are also known as carcinoid tumors.

There are 2 types of carcinoid tumors. Your doctor may refer to them as "functional" or "nonfunctional". Functional carcinoid tumors release large amounts of hormones, such as serotonin, into the body.

It's these excess hormones that can cause a variety of symptoms, including the severe diarrhea and flushing associated with carcinoid syndrome.



Most carcinoid tumors occur in the gastrointestinal tract.

Click here for more facts about carcinoid syndrome



IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN LAR DEPOT (CONTINUED)

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

Before Taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Please see additional Important Safety Information for Sandostatin® LAR Depot (octreotide acetate) for injectable suspension on page 12 and for Sandostatin® (octreotide acetate) Immediate-Release Injection on page 13.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot.





Getting to Know Sandostatin LAR Depot

When you get a diagnosis of severe diarrhea and flushing associated with carcinoid syndrome, it can feel like a lot to handle. Thankfully, there are medicines that can help you control your symptoms. Your doctor may prescribe Sandostatin® (octreotide acetate) Immediate-Release Injection or Sandostatin® LAR Depot (octreotide acetate) for injectable suspension.



Sandostatin has been helping patients for over 30 years[†]

*For all approved indications.
†Includes Sandostatin Immediate-Release Injection and Sandostatin
LAR Depot for all approved indications.

Symptom control you can count on

Here are results from a clinical study of 93 patients with carcinoid syndrome who were treated with Sandostatin LAR Depot or Sandostatin Immediate-Release Injection.





^aA 6-month clinical trial of malignant carcinoid syndrome was performed involving patients who had previously been shown to be responsive to Sandostatin Immediate-Release Injection. Patients received 10-mg, 20-mg, or 30-mg doses of Sandostatin LAR Depot every 28 days or continued their Sandostatin Immediate-Release Injection regimen. Patients receiving Sandostatin LAR Depot who experienced symptom flare-ups were permitted to use supplemental Sandostatin Immediate-Release Injection until symptoms were again controlled to screening frequency.

IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN LAR DEPOT (CONTINUED)

Common Side Effects: Most patients experience side effects at some time. Some common side effects you may experience include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

Other Information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information for Sandostatin LAR Depot on page 12 and for Sandostatin Immediate-Release Injection on page 13.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot.





Treatment With Sandostatin LAR Depot


Two different formulations

Sandostatin is available in 2 formulations, which are administered differently:



- Sandostatin® (octreotide acetate) Immediate-Release Injection, which you self-inject 2 to 4 times per day under the skin of the thigh, upper arm, or abdomen
- Sandostatin® LAR Depot (octreotide acetate) for injectable suspension, which your health care provider administers once every 28 days by injecting it into the buttocks

Your doctor will decide if Sandostatin LAR Depot is right for you based on how your body responds to Sandostatin Immediate-Release Injection.



IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN LAR DEPOT (CONTINUED)

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

Before Taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information for Sandostatin LAR Depot on page 12 and for Sandostatin Immediate-Release Injection on page 13.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot.






This Is RealSupport™

If you have severe diarrhea and flushing associated with carcinoid syndrome, you are not alone. RealSupportTM is here with information and tools that can help you learn to manage your symptoms.

This program does not replace the information provided by your doctor.







For more information about RealSupport $^{\text{TM}}$, please visit us on Facebook: FACEBOOK.COM/SANDOSTATINLARDEPOT



IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN LAR DEPOT (CONTINUED)

Common Side Effects: Most patients experience side effects at some time. Some common side effects you may experience include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

Other Information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

Please see additional Important Safety Information for Sandostatin® LAR Depot (octreotide acetate) for injectable suspension on page 12 and for Sandostatin® (octreotide acetate) Immediate-Release Injection on page 13.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot.





Living With Carcinoid Syndrome

In addition to your current treatment plan, there are things you can do to take an active role in managing the severe diarrhea and flushing associated with carcinoid syndrome. Be sure to discuss your plan with your health care team. Here are some tips to help get you started:



Partner with your health care team

- Always provide accurate information about all symptoms you experience, including the severity and changes over time
- Ask questions about your disease, the management of your health, and any other concerns



Keep a regular appointment schedule

- Making a commitment to keeping your medical appointments can help you establish
 a partnership with your health care team
- You can **download our nutrition journal and appointment tracker** to help keep track of your diet and upcoming doctor appointments



Keep a diary of symptoms and test results

 You can help your health care team manage your disease by keeping a diary of symptoms and test results



Maintain a positive attitude

- It's not always easy, but maintaining a positive attitude is very important for anyone with a serious medical condition
- Remind yourself that you are more than your disease



Think you know all your potential symptom triggers?

Learn more about lifestyle choices that may have an impact



Please see additional Important Safety Information for Sandostatin® LAR Depot (octreotide acetate) for injectable suspension on page 12 and for Sandostatin® (octreotide acetate) Immediate-Release Injection on page 13.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot.






Food and Diet Changes

When you're managing the severe diarrhea and flushing associated with carcinoid syndrome, watching what you eat may help you avoid some symptoms or symptom flare-ups. But that doesn't mean that mealtimes have to be boring.

Remember, changes in your diet are meant to complement your current treatment, not replace it. Be sure to talk to your doctor before making dietary changes.





For dozens of snack and meal ideas visit our Recipe Filter page



IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN LAR DEPOT (CONTINUED)

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

Before Taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Please see additional Important Safety Information for Sandostatin® LAR Depot (octreotide acetate) for injectable suspension on page 12 and for Sandostatin® (octreotide acetate) Immediate-Release Injection on page 13.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot.





Carcinoid Syndrome Support Groups

Building a support network is a great way to get involved in your care. See the list of groups and organizations* who are ready to support you.

Carcinoid Cancer Foundation (CCF)

1-888-722-3132 (toll free)



www.carcinoid.org

Healing NET Foundation



1-615-369-6463



www.thehealingnet.org

Neuroendocrine Tumor Research Foundation (NETRF)



1-617-946-1780



www.netrf.org

Neuroendocrine Cancer Awareness Network (NCAN)



1-866-850-9555 (toll free)



www.netcancerawareness.org

Los Angeles Carcinoid Neuroendocrine Tumor Society (LACNETS)



www.lacnets.org

NorCal CarciNET Community



www.norcalcarcinet.org

*These websites are maintained by third parties. Novartis Pharmaceuticals Corporation does not guarantee the accuracy, completeness, or any other aspect of the information on these sites.



JOIN US ON FACEBOOK

For more information about RealSupport™ or to stay connected with us, please visit us at facebook.com/SandostatinLARDepot or "Like" our page to join us.



IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN LAR DEPOT (CONTINUED)

Common Side Effects: Most patients experience side effects at some time. Some common side effects you may experience include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

Other Information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information for Sandostatin® LAR Depot (octreotide acetate) for injectable suspension on page 12 and for Sandostatin® (octreotide acetate) Immediate-Release Injection on page 13.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot.





Resources and Support



Mobile Administration Program (MAP)

Our nurses are there for you, at no charge*†

- Through the MAP program, a trained health care professional will prepare and administer Sandostatin® LAR Depot (octreotide acetate) for injectable suspension to you at a location that is convenient for you, such as your home⁺, at no charge to you or your health insurance plans
- During the COVID-19 pandemic, Novartis is temporarily modifying the program to include patients with any insurance type

LEARN MORE ABOUT MAP ▶

- *Limitations apply. Novartis reserves the right to update limitations and eligibility at any time.
- [†]The program does not replace professional care or the authority of the prescribing physician. Patients still keep their regularly scheduled physician checkups. First dose must be administered by prescribing physician.



Patient Assistance Now Oncology (PANO)

Our Patient Assistance Now Oncology (PANO) program was created to assist you with accessing your Novartis medicine(s)—from insurance verification to financial assistance—all through a knowledgeable and supportive call center.

To learn more, call 1-800-282-7630 or visit Patient.NovartisOncology.com. ▶



Universal Co-pay Program

You may be eligible for immediate co-pay savings on your next prescription of Sandostatin LAR Depot.

- Eligible patients may pay \$25 per month
- Novartis will pay the remaining co-pay, up to \$15,000 per calendar year, per product^t

To find out if you are eligible for the Universal Co-pay Program, call **1-877-577-7756** or visit **Copay.NovartisOncology.com**. ▶

¹Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice.

For full terms and conditions, visit www.Copay.NovartisOncology.com or call 1-877-577-7756.

IMPORTANT SAFETY INFORMATION FOR SANDOSTATIN LAR DEPOT (CONTINUED)

Warnings and Precautions: Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

Before Taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including: cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Please see additional Important Safety Information for Sandostatin LAR Depot on page 12 and for Sandostatin® (octreotide acetate) Immediate-Release Injection on page 13.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot.





FAQs

You have questions, we have answers.

Q: How does Sandostatin® LAR Depot (octreotide acetate) for injectable suspension work?

A: Sandostatin LAR Depot is similar to somatostatin, a hormone that occurs naturally in the body. Both work in the same way to reduce excess hormones and other metabolic activities involved in carcinoid syndrome and VIPomas*. Sandostatin LAR Depot remains in the body much longer than somatostatin.

Q: What dose of Sandostatin LAR Depot is right for me?

A: Sandostatin LAR Depot comes in 3 doses. Talk to your doctor to find out which dose is right for you.

Q: Can I administer Sandostatin LAR Depot to myself?

A: No, Sandostatin LAR Depot should be administered only by a trained health care provider.

Q: How much does Sandostatin LAR Depot cost?

A: How much the drug will cost depends on where it is dispensed and what your individual insurance plan may cover. This amount can vary.

Q: How can I get help paying for my Sandostatin LAR Depot?

A: <u>Click here</u> to learn about the Novartis Oncology Universal Co-pay Card program.

Q: Can I stop taking Sandostatin LAR Depot if I feel better?

A: You should consult with your health care provider. You may feel better because of the action of Sandostatin LAR Depot, but the underlying problem still exists.

*VIPomas, vasoactive intestinal peptide tumors.

Q: What should I do if I miss an appointment?

A: If you miss your appointment for your injection, you should call your health care provider's office immediately to reschedule your visit. If keeping office appointments is difficult for you, talk with your health care provider about possible home visits.



Q: What are the possible side effects of Sandostatin LAR Depot, which is taken to treat the severe diarrhea and flushing associated with carcinoid syndrome?

A: Most patients experience side effects at some time. Treatment with Sandostatin LAR Depot may affect gallbladder function, sugar metabolism, thyroid and heart function, and nutritional absorption, which may require monitoring by your doctor. Some common side effects you may experience include: back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional Important Safety Information for Sandostatin LAR Depot on page 12 and for Sandostatin® (octreotide acetate) Immediate-Release Injection on page 13.

Please click here for full Prescribing Information for Sandostatin Immediate-Release Injection and click here for Sandostatin LAR Depot.





IMPORTANT SAFETY INFORMATION

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension

Warnings and Precautions: Treatment with Sandostatin® LAR Depot (octreotide acetate) for injectable suspension may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

Before Taking Sandostatin LAR Depot: Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

Common Side Effects: Most patients experience side effects at some time. Some common side effects you may experience include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

Other Information: Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

Indications and Usage

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for

- Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
- Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors

In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please click here for full Prescribing Information for Sandostatin LAR Depot.





IMPORTANT SAFETY INFORMATION

Sandostatin® (octreotide acetate) Immediate-Release Injection

Warnings and Precautions: Treatment with Sandostatin® (octreotide acetate) Immediate-Release Injection may affect gallbladder function, with postmarketing reports of gallstones resulting in complications requiring surgical removal of the gallbladder; sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications (eg, inflammation of the gallbladder, bile duct, or pancreas).

Before Taking Sandostatin Injection: Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, calcium channel blockers, agents to control fluid and electrolyte balance, and bromocriptine.

Common Side Effects: Most patients experience side effects at some time. Some Common Side Effects you may experience include gallstones, heart function changes, diarrhea, loose stools, nausea, abdominal discomfort, flatulence, blood sugar changes, underactive thyroid gland including enlarged thyroid gland, pain on injection, headache, dizziness and inflammation of the pancreas.

Other Information: Women of child bearing potential should use adequate contraception during treatment. Talk to your doctor if you are a nursing mother. Diabetic patients should monitor their blood sugar levels frequently. Patients should make sure they are carefully instructed in the correct sterile injection technique before using Sandostatin Injection.

Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms. Patients with acromegaly should adhere to their return visit schedule to help assure steady control of GH and IGF-1 levels.

INDICATIONS AND USAGE

Sandostatin Injection is a prescription medicine indicated for:

- Treatment of acromegalic patients who have had inadequate response to or cannot be treated with surgery, radiotherapy, and bromocriptine mesylate at maximally tolerated doses (the goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal)
- Treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
- · Treatment of the profuse watery diarrhea associated with VIP-secreting tumors

The effect of Sandostatin Injection on tumor size, rate of growth, and development of metastases has not been determined. In patients with acromegaly, improvement in clinical signs and symptoms was not shown in clinical trials.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please <u>click here</u> for full Prescribing Information for Sandostatin Immediate-Release Injection.





IS YOUR MIND SPINNING WITH QUESTIONS AND INFORMATION? Write or type your notes here:



You can also **download our nutrition journal and appointment tracker** for even more space to help keep track of your diet and upcoming doctor appointments.



Please see additional Important Safety Information for Sandostatin[®] LAR Depot (octreotide acetate) for injectable suspension on page 12 and for Sandostatin[®] (octreotide acetate) Immediate-Release Injection on page 13.

Please <u>click here</u> for full Prescribing Information for Sandostatin Immediate-Release Injection and <u>click here</u> for Sandostatin LAR Depot.



